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Background: Bone marrow transplantation is a complex and
often overwhelming experience for patients and their families. The
discharge teaching manual that was being used contained informa-
tion that was minimal and outdated to prepare patients and their
families for recovery after discharge. Inconsistent information was
given to patients among inpatient staff as well as inconsistencies in
education between inpatient and outpatient staff.
Purpose and Objectives: The purpose of this project was to
elaborate and update the extraordinary amount of available infor-
mation for patients and their families into one consistent format. A
discharge teaching pamphlet was developed in order to 1) stan-
dardize information given to patients by nursing staff including
both the inpatient and outpatient settings; 2) provide educational
information below an eighth grade level; and 3) develop an ex-
panded, research-based patient education tool reﬂective of national
standards
Method: The Resource Nurse contacted the CDC, ONS,
IBWA, and three other transplant centers for current practice and
teaching materials. Relevant Barnes-Jewish Hospital policies were
reviewed to verify compliance of educational materials. The gath-
ered information was reviewed by BMT Clinical Nurse Specialists,
Nurse Practitioners, coordinators, pharmacists, social worker and
editorial staff.
Results: The material was published as a professional, colored
pamphlet entitled “Recovery”. All BMT staff was educated to
ensure consistent understanding of information to be provided to
patients. An informal survey of patients who had received “Recov-
ery” found many positive comments from patients and families.
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DEVELOPMENT OF A PEDIATRIC HPC DONOR HISTORY QUESTION-
NAIRE (DHQ)
Halverson, T.L.1 1Children’s Memorial Hospital, Chicago, IL.
Utilizing an adult-oriented donor history questionnaire (DHQ)
to determine donor eligibility for a pediatric donor poses unique
challenges. Questions designed to elicit information about poten-
tial communicable disease risks in adults can be unnecessarily
repetitive or conﬂict with state requirements for pediatric patients.
This has led Children’s Memorial Hospital (CMH) to develop a
pediatric HPC DHQ.
The newly-released (adult) HPC DHQ was developed by an
inter-organizational Donor History Questionnaire-Cellular Ther-
apies Task Force to screen allogeneic hematopoietic progenitor
cell (HPC) donors for communicable disease risk factors in accor-
dance with requirements from the FDA, NMDP, AABB and
FACT. User instructions that accompany the (adult) HPC DHQ
recommend administering the questions without changing the or-
der, wording or content. The (adult) HPC DHQ contains 44
questions; 13 of these questions are related to sexual activity and
sexually transmitted diseases.
In the state of Illinois, children between the ages of 12 and 17
must speciﬁcally authorize release of information pertaining to
sexually transmitted diseases and other “highly conﬁdential” health
information. Therefore, DHQ questions relating to sexually trans-
mitted diseases need to be asked while the parents are not present,
and afﬁrmative responses cannot be shared with the parents / legal
guardians without express written authorization by the 12 to 17
year old child. The order of questions in the newly-released HPC
DHQ hinders separate administration of those questions and thus
compliance with state regulations.
An informal survey of other pediatric transplant facilities across
the United States found signiﬁcant variation in the way that DHQs
were administered to potential pediatric donors. Some institutions
administered each DHQ question to the potential donor’s parents,
while others glossed over or omitted questions relating to sexual
activity when they did not seem relevant. Several respondents
noted the need for a pediatric-oriented HPC DHQ.
To fulﬁll the FDA’s requirement for proper determination of
donor eligibility and adhere to state requirements regarding shar-
ing of “highly conﬁdential” health information in adolescent pa-
tients, CMH’s Stem Cell Transplant Program developed and is
currently adopting a pediatric HPC DHQ that streamlines the
interview process while appropriately screening for potential com-
municable disease risks in the pediatric donor.
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A REIMMUNIZATION PROGRAM FOR PEDIATRIC HEMATOPOIETIC PRO-
GENITOR CELL TRANSPLANT (HPCT) RECIPIENTS
Klinger, E.F.1, Daum, C.D.1 1Children’s Hospital of Orange County,
Orange, CA.
“During the ﬁrst 1-4 years after an allogeneic or autologous
HPCT, antibody titers to vaccine-preventable diseases (e.g., teta-
nus, polio, measles) decline if the recipient is not reimmunized.
Despite return of normal neutrophil and lymphocyte counts, hu-
moral and cellular immunity may take as long as one year to fully
recover after HPCT and these diseases can pose increased risk for
HPCT recipients. To acquire the same immunity as others,
HPCT recipients should be routinely reimmunized. The timing of
reimmunization is dependent upon the type of transplant, the type
of immunosuppressive therapy, and whether or not chronic graft
versus host disease has developed.”(CDC guidelines, 2000 and
Avigan et al, 2001) The Children’s Hospital of Orange County
(CHOC) Blood and Marrow Transplant team developed a pro-
gram that addresses the need for reimmunization of the HPCT
recipient population that 1) increases identiﬁcation and evaluation
of HPCT recipients, 2) communicates current CDC recommen-
dations to medical staff, 3) documents vaccinations utilizing exist-
ing organizational and statewide immunization programs, and 4)
improves overall reimmunization implementation . An immuniza-
tion alert for evaluation 1-year post HPCT is posted on the
patient’s chart. Once deemed eligible, the patient elects to receive
the vaccinations at either CHOC or their community-based phy-
sician’s ofﬁce. The primary physician’s ofﬁce receives a 3  5 inch
abbreviated copy of the CDC recommendations attached to the
yellow California “Immunization Record” card and vaccinations
may be documented on any California Immunization Record form.
Patients receiving vaccinations at CHOC utilizes the organiza-
tional immunization record form with the CDC recommendations
printed on the back for reference. The implementation of this
program ensures that HPCT recipients will experience the same
baseline immunity as others as they return to normalcy.
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THE DEVELOPMENT OF A COMPREHENSIVE QUALITY MANAGEMENT
PLAN IN THE BLOOD AND MARROW STEM CELL TRANSPLANT SETTING
Kurosky, A.S.1, DiBiase, R.1, Carolin, K.1 1Karmanos Cancer Institute,
Detroit, MI.
Background: Quality management (QM) is an essential activity
for blood and marrow stem cell transplant (BMT) programs seek-
ing accreditation by the Foundation for Accreditation of Cellular
Therapy (FACT). It is also an area where deﬁciencies are often
observed by FACT inspectors. The components of a health care
quality management plan (QMP) include the development of a
model for health care improvement that promotes best practice
standards, utilizes these practice standards to guide the manage-
ment of patient care, measures outcomes, and improves critical
processes and practices based on the analysis of outcomes. Our
BMT program’s QMP satisﬁed regulatory requirements but the
structure lacked translation into substantive outcome analysis and
changes if indicated. A restructure of the plan was initiated to
capture these essential components of QM. FRAMEWORK: Rec-
ognizing that the activities of hematopoietic progenitor cell col-
lection, processing and the clinical care of patients receiving a
transplant are integrated, the BMT program within this National
Cancer Institute designated comprehensive cancer facility devel-
oped a multi-disciplinary QMP. An overview of the design and
implementation of the QMP will be presented including: a) the
organizational structure of the QM committee including the lead-
ership with ﬁnal responsibility for the QMP and the personnel
responsible for execution of key activities; b) identiﬁcation and
development of pertinent policies and procedures in collection,
laboratory and clinical facilities and those shared across the pro-
gram; c) selection of key measures and processes for audit and
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